In patients with high-risk melanoma, the personalized cancer vaccine intismeran autogene and Keytruda reduced the risk of ...
Among patients with advanced melanoma, long-term data have shown that a personalized mRNA cancer vaccine, when combined with ...
Moderna (MRNA) stock is in focus as the mRNA-based cancer drug with Merck's (MRK) Keytruda cut melanoma recurrence/death risk ...
GlobalData on MSN
Moderna’s cancer vaccine plus Keytruda boosts RFS in melanoma study
A combination of intismeran autogene and Keytruda significantly prolonged recurrence-free survival in melanoma.
The experimental mRNA-based drug sharply reduced the risk of recurrence or death when combined with immunotherapy Keytruda, ...
In a small clinical trial, customized mRNA vaccines against high-risk skin cancers appeared to reduce the risk of cancer recurrence and death by nearly 50 percent over five years when compared with ...
The companies have an expansive clinical program for the mRNA neoantigen therapy intismeran autogene in combination with ...
At five years, KEYTRUDA plus LENVIMA showed a 16.7% overall survival (OS) rate for these patients with mismatch repair proficient (pMMR) advanced endometrial carcinoma versus 7.3% for chemotherapy ...
Gilead Sciences, Inc. (Nasdaq: GILD) today announced The New England Journal of Medicine (NEJM) published the full results from the positive Phase 3 ASCENT-04/KEYNOTE-D19 study evaluating the ...
PADCEV plus KEYTRUDA is the first and only regimen to improve survival when used before and after standard of care in cisplatin-ineligible patients with muscle-invasive bladder cancer Results will be ...
PADCEV plus KEYTRUDA is the first and only regimen to improve survival when used before and after standard of care (surgical cystectomy) in cisplatin-ineligible patients with muscle-invasive bladder ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results